Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;131(1):11-22.
doi: 10.1111/jam.14949. Epub 2020 Dec 9.

Biofilm of Candida albicans: formation, regulation and resistance

R Pereira  1 , R O Dos Santos Fontenelle  2 , E H S de Brito  3 , S M de Morais  4
Affiliations
Review

Biofilm of Candida albicans: formation, regulation and resistance

R Pereira et al. J Appl Microbiol. 2021 Jul.

Abstract

Candida albicans is the most common human fungal pathogen, causing infections that range from mucous membranes to systemic infections. The present article provides an overview of C. albicans, with the production of biofilms produced by this fungus, as well as reporting the classes of antifungals used to fight such infections, together with the resistance mechanisms to these drugs. Candida albicans is highly adaptable, enabling the transition from commensal to pathogen due to a repertoire of virulence factors. Specifically, the ability to change morphology and form biofilms is central to the pathogenesis of C. albicans. Indeed, most infections by this pathogen are associated with the formation of biofilms on surfaces of hosts or medical devices, causing high morbidity and mortality. Significantly, biofilms formed by C. albicans are inherently tolerant to antimicrobial therapy, so the susceptibility of C. albicans biofilms to current therapeutic agents remains low. Therefore, it is difficult to predict which molecules will emerge as new clinical antifungals. The biofilm formation of C. albicans has been causing impacts on susceptibility to antifungals, leading to resistance, which demonstrates the importance of research aimed at the prevention and control of these clinical microbial communities.

Keywords: biofilms; infection; pathogenesis; resistance; virulence.

PubMed Disclaimer

References

    1. Agarwal, A.K., Rogers, P.D., Baerson, S.R., Jacob, M.R., Barker, K.S., Cleary, J.D., Walker, L.A., Nagle, D.G. et al. (2003) Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J Biol Chem 278, 34998-35015.
    1. Akins, R.A. (2005) An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol 43, 285-318.
    1. Albuquerque, P. and Casadevall, A. (2012) Quorum sensing in fungi-a review. Med Mycol 50, 337-345.
    1. Alexander, B.D., Johnson, M.D., Pfeiffer, C.D., Jimffenez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S.A. et al. (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 26, 1724-1732.
    1. Al-Fattani, M.A. and Douglas, L.J. (2006) Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J Med Microbiol 55, 999-1008.

MeSH terms

Substances